Literature DB >> 9516975

RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features.

I Bongarzone1, P Vigneri, L Mariani, P Collini, S Pilotti, M A Pierotti.   

Abstract

The papillary carcinoma family (PCF) of thyroid tumors includes a wide variety of neoplastic entities regarded as well-differentiated, poorly differentiated, and undifferentiated papillary thyroid carcinomas. Recent studies have established the presence of alternative oncogenic rearrangements of the RET and NTRK1 genes in a consistent fraction (< or = 50%) of papillary thyroid tumors. RET oncogenic rearrangements are also very frequent (approximately 60%) in Chernobyl radiation-associated papillary thyroid neoplasias, which show an increased aggressiveness in terms of pathological stage at disease onset. These observations prompted us to study the relationship between the presence or absence of RET and NTRK1 oncogenes and the clinicopathological features (age, sex, histopathology, and pTNMC2 staging) of 76 consecutive, non-radiation-related tumors of the PCF. As previously reported, statistical univariate analysis revealed a correlation between the combination of RET and NTRK1 (RET/NTRK1) positivity and young age of patients at diagnosis. In addition, a significant association was found between RET/NTRK1 positivity and locally advanced stage of disease at presentation (pT4: P < 0.015). The multivariate analysis confirmed that RET/NTRK1 activation parallels an unfavorable disease presentation, which may correlate with a less favorable disease outcome. Furthermore, within the PCF, the frequency of RET/NTRK1 positivity was not influenced by the different neoplastic subtypes or the tumor versus degree of differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516975

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.

Authors:  P Jagan Mohan Rao; N V Vardhini; M V S Parvathi; P Balakrishna Murthy; G Sudhakar
Journal:  Tumour Biol       Date:  2014-06-24

Review 2.  Coding Molecular Determinants of Thyroid Cancer Development and Progression.

Authors:  Veronica Valvo; Carmelo Nucera
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-23       Impact factor: 4.741

Review 3.  Molecular analysis of thyroid tumors.

Authors:  Feriyl Bhaijee; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

4.  Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).

Authors:  Ying-Hsia Chu; Dora Dias-Santagata; Alexander A Farahani; Baris Boyraz; William C Faquin; Vânia Nosé; Peter M Sadow
Journal:  Mod Pathol       Date:  2020-05-26       Impact factor: 7.842

Review 5.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

Review 6.  Oncogenic gene fusions in epithelial carcinomas.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Curr Opin Genet Dev       Date:  2009-02-21       Impact factor: 5.578

7.  Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Authors:  Alexander Drilon; Lu Wang; Adnan Hasanovic; Yoshiyuki Suehara; Doron Lipson; Phil Stephens; Jeffrey Ross; Vincent Miller; Michelle Ginsberg; Maureen F Zakowski; Mark G Kris; Marc Ladanyi; Naiyer Rizvi
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

8.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

9.  Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers.

Authors:  David Tai; Donald Poon
Journal:  J Oncol       Date:  2010-08-24       Impact factor: 4.375

Review 10.  New targets in non-small cell lung cancer.

Authors:  Shirish M Gadgeel
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.